Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Apellis Pharmaceuticals Inc. currently manages 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 6 pending office actions are being handled by 6 distinct examiners, indicating a completely decentralized review process where each active application is subject to a different examiner's scrutiny. This lack of overlap among examiners means that the applicant must prepare for 6 potentially different sets of examination priorities and styles.
The prosecution is spread across 5 distinct art units, which suggests that the company's research in Biotechnology & Pharmaceuticals touches upon multiple specialized fields. GARYU, LIANKO G is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because the busiest examiner handles only 1 pending office action, the workload is distributed evenly across the 6 distinct examiners currently engaged with the portfolio.
For patent practitioners, the involvement of 5 distinct art units means that the 6 pending office actions may be subject to different internal guidelines or average pendency rates. The fact that 6 distinct examiners are involved for only 6 pending office actions highlights a high degree of variety in the prosecution landscape. Success in this portfolio requires a tailored approach for each application to satisfy the specific requirements of GARYU, LIANKO G and the other five officials.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Multi-statute (no §101) | 5 (83%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GARYU, LIANKO G | 1 | 66.0% | +45.4% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| HUMPHRIES, NICHOLAS ADAM | 1 | 34.2% | +76.6% |
| SABILA, MERCY HELLEN | 1 | 57.5% | +45.3% |
| HUDSON, AMY ROSE | 1 | 74.8% | +11.7% |
| HOWARD, ZACHARY C | 1 | 63.9% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027331 | METHODS OF TREATING EYE DISORDERS | SABILA, MERCY HELLEN | 22d |
| 18386542 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | GARYU, LIANKO G | 84d |
| 18282664 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AEDER, SEAN E | — |
| 18266464 | GENOMIC EDITING OF COMPLEMENT | HUMPHRIES, NICHOLAS ADAM | — |
| 17791194 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027331 | METHODS OF TREATING EYE DISORDERS | SABILA, MERCY HELLEN | 22d |
| 17798339 | RNAS FOR COMPLEMENT INHIBITION | HUDSON, AMY ROSE | 26d |
| 18386542 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | GARYU, LIANKO G | 84d |
| 18282664 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AEDER, SEAN E | — |
| 18266464 | GENOMIC EDITING OF COMPLEMENT | HUMPHRIES, NICHOLAS ADAM | — |
| 17791194 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | HOWARD, ZACHARY C | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1642 | 1 |
| 1631 | 1 |
| 1636 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18386542 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | GARYU, LIANKO G | 1654 | §103§112Other | Non-Final OA | 84d | Pending | Nov 02, 2023 |
| 18282664 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AEDER, SEAN E | 1642 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18266464 | GENOMIC EDITING OF COMPLEMENT | HUMPHRIES, NICHOLAS ADAM | 1631 | §103§112Other | Non-Final OA | — | Pending | Jun 09, 2023 |
| 18027331 | METHODS OF TREATING EYE DISORDERS | SABILA, MERCY HELLEN | 1654 | §102§103§112 | Non-Final OA | 22d | Pending | Mar 20, 2023 |
| 17798339 | RNAS FOR COMPLEMENT INHIBITION | HUDSON, AMY ROSE | 1636 | §103 | Non-Final OA | 26d | Pending | Aug 09, 2022 |
| 17791194 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | — | Pending | Jul 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApellis Pharmaceuticals Inc. has 6 pending office actions as of October 2026, spread across 5 art units and 6 examiners.
Lianko G Garyu has the most, with 1 of Apellis Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
